Page last updated: 2024-12-11

sanglifehrin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5388925
CHEMBL ID410807
SCHEMBL ID2587742
MeSH IDM0336977

Synonyms (11)

Synonym
1YND
DB03393
sanglifehrin a
SFA ,
CHEMBL410807
SCHEMBL2587742
(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-{(1e,3e,7s,8s)-9-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4-hydroxy-3,5,11-trimethyl-8-oxo-1-oxa-7-azaspiro[5.5]undec-2-yl]-8-hydroxy-1,7-dimethylnona-1,3-dien-1-yl}-10,12-dihydroxy-3-(3-hydroxybenzyl)-11-methyl-6-(1-meth
Q27465336
ONJZYZYZIKTIEG-CFBQITSMSA-N
bdbm50218665
DTXSID101022539

Research Excerpts

Overview

Sanglifehrin A (SFA) is a spirolactam-conjugated, 22-membered macrolide with remarkable immunosuppressive and antiviral activities. The immunobiology of action is poorly understood.

ExcerptReferenceRelevance
"Sanglifehrin A (SFA) is a novel immunosuppressant isolated from Streptomyces sp. "( Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution.
Kallen, J; Sedrani, R; Wagner, J; Zenke, G, 2005
)
2
"Sanglifehrin A (SFA) is a spirolactam-conjugated, 22-membered macrolide with remarkable immunosuppressive and antiviral activities. "( Formation and Loading of a (2S)-2-Ethylmalonamyl Starter Unit in the Assembly Line of Polyketide-Nonribosomal Peptide Hybrid Sanglifehrin A.
Guo, S; Liu, C; Liu, W; Pang, B; Qu, X; Tang, Z, 2023
)
2.56
"Sanglifehrin A (SFA) is a mixed polyketide and non-ribosomal peptide synthase natural product with sub-nano-molar affinity for its receptor cyclophilin A (PPIA)."( IMPDH2 Is an Intracellular Target of the Cyclophilin A and Sanglifehrin A Complex.
Pua, KH; Sowa, ME; Stiles, DT; Verdine, GL, 2017
)
1.42
"Sanglifehrin A (SFA) is a cyclophilin-binding immunosuppressant but the immunobiology of action is poorly understood. "( The cyclophilin-binding agent Sanglifehrin A is a dendritic cell chemokine and migration inhibitor.
Baal, N; Bechtel, J; Bein, G; Hackstein, H; Immecke, SN; Knoche, A; Wilhelm, J, 2011
)
2.1
"Sanglifehrin A (SFA) is a novel immunosuppressive natural product isolated from Streptomyces sp. "( Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data.
France, J; Jutzi Eme, AM; Kallen, J; Martin Cabrejas, LM; Oberer, L; Papageorgiou, CD; Rihs, G; Rohrbach, S; Sedrani, R; Senia, F; Thai, B; Wagner, D; Wagner, J; Zenke, G, 2003
)
1.76
"Sanglifehrin A (SFA) is a novel cyclophilin-binding immunosuppressant with an unknown mechanism of action. "( Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells.
Bein, G; Hackstein, H; Steinschulte, C; Taner, T; Thomson, AW, 2003
)
2.12
"Sanglifehrin A (SFA) is a recently discovered immunosuppressant drug that shares its intracellular target with the major immunosuppressant drug cyclosporin A (CsA). "( Cyclophilin sensitivity to sanglifehrin A can be correlated to the same specific tryptophan residue as cyclosporin A.
Kay, JE; Pemberton, TJ, 2003
)
2.06
"Sanglifehrin A (SFA) is a recently developed immunosuppressant that belongs to the family of immunophilin-binding ligands. "( The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells.
Schlagwein, N; van der Kooij, SW; van Kooten, C; Woltman, AM, 2004
)
2.04
"Sanglifehrin A is a novel complex natural product showing strong immunosuppressive activity and remarkably high affinity for cyclophilin A."( Efficient synthesis of [3H]-sanglifehrin A via selective oxidation/reduction of alcohols at C31 and C35.
Andres, H; France, J; Oberer, L; Rohrbach, S; Wagner, D; Wagner, J, 2005
)
1.34
"Sanglifehrin A (SFA) is a novel compound with unsurpassed cyclophilin-binding affinity, but relatively low direct antilymphocytic activity. "( Sanglifehrin a blocks key dendritic cell functions in vivo and promotes long-term allograft survival together with low-dose CsA.
Bein, G; Eisele, A; Fiedel, S; Hackstein, H; Hölschermann, H; Rathke, V; Stadlbauer, T; Steinschulte, C; Taner, T; Thomson, AW; Tillmanns, H, 2007
)
3.23
"Sanglifehrin A (SFA) is a novel immunosuppressive natural product that binds to cyclophilin but is structurally distinct from cyclosporin A (CsA). "( Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle.
Liu, JO; Zhang, LH, 2001
)
3.2

Treatment

ExcerptReferenceRelevance
"How sanglifehrin A treatment leads to the cell cycle blockade has remained unknown."( Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53.
Liu, JO; Youn, HD; Zhang, LH, 2001
)
1.03

Bioavailability

ExcerptReferenceRelevance
" This observation allowed further simplifications of the scaffold to generate new lead compounds in the search for orally bioavailable cyclophilin inhibitors."( Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
Appleby, TC; Austin, CA; Dean, DK; Fliri, HG; Frey, CR; Jansa, P; Jin, D; Keats, AJ; Lazarides, L; Leavitt, SA; Lee, YJ; Liclican, AC; Mackman, RL; Pettit, SB; Poullennec, KG; Sanvoisin, JA; Schmitz, U; Schultz, BE; Stanway, SJ; Steadman, VA; Tian, Y; Watt, GM; Wong, MH, 2017
)
0.68

Dosage Studied

ExcerptRelevanceReference
" However, unlike CsA, the dose-response curve for inhibition by SfA is sigmoidal rather than hyperbolic, suggesting a multimeric structure for the MPTP with cooperativity between subunits."( Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A.
Clarke, SJ; Halestrap, AP; McStay, GP, 2002
)
1.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Peptidyl-prolyl cis-trans isomerase AHomo sapiens (human)IC50 (µMol)0.00360.00360.00360.0036AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidyl-prolyl cis-trans isomerase A Homo sapiens (human)Kd0.00330.00220.42976.4200AID1362385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein phosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein phosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein kinase activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
apoptotic processPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
viral release from host cellPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
platelet activationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
neuron differentiationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
neutrophil chemotaxisPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
leukocyte chemotaxisPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
activation of protein kinase B activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of stress-activated MAPK cascadePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
lipid droplet organizationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cellular response to oxidative stressPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein dephosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
endothelial cell activationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of MAPK cascadePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
regulation of viral genome replicationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of viral genome replicationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein secretionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cell adhesion molecule productionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein K48-linked ubiquitinationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
platelet aggregationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of viral life cyclePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
regulation of apoptotic signaling pathwayPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
RNA bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
integrin bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cyclosporin A bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
virion bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
unfolded protein bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
heparan sulfate bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
extracellular spacePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
nucleusPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
focal adhesionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
vesiclePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
secretory granule lumenPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
ficolin-1-rich granule lumenPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein-containing complexPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID226694Immunosuppressive activity was assessed by mixed lymphocyte reaction relative to Sanglifehrin A2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions.
AID1362385Inhibition of Cy5-labeled cyclosporin A binding to full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) after 30 mins by TR-FRET assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID226987Permeation ratio of cell-free CyP binding to intracellular CyP binding2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions.
AID54731Mean relative IC50 intracellular CyP-binding was assessed by competition with the whole cell and [3H]cyclosporine A relative to Sanglifehrin A2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions.
AID54730Mean relative IC50 cell free CyP-binding was assessed by competition with the interaction of CyP-A and relative to sanglifehrin A2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005The Journal of biological chemistry, Jun-10, Volume: 280, Issue:23
Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution.
AID1811Experimentally measured binding affinity data derived from PDB2005The Journal of biological chemistry, Jun-10, Volume: 280, Issue:23
Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (3.64)18.2507
2000's29 (52.73)29.6817
2010's21 (38.18)24.3611
2020's3 (5.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.62 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (98.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]